Stuttgart - Delayed Quote EUR

AC Immune SA (IMR.SG)

1.3560

+0.0800

+(6.27%)

At close: 9:30:33 PM GMT+2

AC Immune reports interim outcomes from trial of Parkinson’s therapy

The adaptive and biomarker-based trial comprises two parts and focuses on subjects with early PD.

Clinical Trials Arena 20 days ago

ACIU
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease

AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein (a-syn) antibody levels on average over 20-fold higher than placebo after 4 immunizationsRepeated immunizations amplify the anti-a-syn antibody response, supporting boostability and the potential to further increase antibody titersACI-7104.056 is well tolerated with no safety issues reported to

GlobeNewswire 21 days ago

ACIU
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025

AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 AC Immune to host symposium highlighting the company’s industry-leading pipeline of active immunotherapies for precision prevention of neurodegenerative diseasesMultiple presentations at the International Conference on Alzheimer’s and Parkinson’s Disease (AD/PD™ 2025) showcasing the diversity of the company’s precision medicine pipeline Lausanne, Switzerland, March 25, 2025 – AC Immune SA (

GlobeNewswire 29 days ago

ACIU
ACIU Stock Crashes 18.3% in a Month: Buy, Sell or Hold?

AC Immune's shares decline 18.3% in a month. While the company's pipeline progress is encouraging, we advise investors to remain on the sidelines for now.

Zacks 30 days ago

ACIU

JNJ
AC Immune (NASDAQ:ACIU) investors are sitting on a loss of 52% if they invested five years ago

Statistically speaking, long term investing is a profitable endeavour. But unfortunately, some companies simply don't...

Simply Wall St. last month

ACIU
AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update

AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update Landmark exclusive option and license deal with Takeda for ACI-24.060 with $100 million upfront and additional potential milestones of up to about $2.1 billion plus royalties on sales upon commercializationACI-24.060 ABATE Phase 1b/2 trial showed encouraging interim safety and tolerability data in Down syndrome (DS) cohort; further interim results in Alzheimer’s disease (AD) and DS expected in 2025Enrollment progr

GlobeNewswire last month

ACIU
AC Immune (ACIU) Upgraded to Strong Buy: Here's What You Should Know

AC Immune (ACIU) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks last month

ACIU
AC Immune to Participate in Upcoming Investor Conferences

AC Immune to Participate in Upcoming Investor Conferences Lausanne, Switzerland, March 4, 2025 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the company's management will participate in the following investor conferences in March: Leerink Partners 2025 Global Healthcare Conference,Management will participate in investor meetings on March 10, 2025Barclays 27th Annual Global Healthcare Co

GlobeNewswire last month

ACIU
Down -9.7% in 4 Weeks, Here's Why You Should You Buy the Dip in AC Immune (ACIU)

The heavy selling pressure might have exhausted for AC Immune (ACIU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks 2 months ago

ACIU
3 US Penny Stocks With Market Caps Over $100M To Consider

As January comes to a close, the U.S. stock market has experienced a mix of volatility and growth, with major indexes posting gains despite recent tariff announcements. In this context, penny stocks—often representing smaller or newer companies—remain an intriguing investment area due to their potential for growth at affordable price points. While the term may seem outdated, these stocks can offer opportunities when backed by strong financials and solid fundamentals.

Simply Wall St. 2 months ago

ACIU

NEOV

NEOVW
US Penny Stocks Spotlight: AC Immune And Two Others To Consider

As the U.S. equities market starts the new year with a continued slump, investors are closely monitoring opportunities that might emerge amidst broader market challenges. Penny stocks, often representing smaller or newer companies, remain an intriguing niche for those seeking growth potential beyond the well-trodden paths of large-cap investments. Despite their vintage name, these stocks can still offer surprising value and stability when backed by solid financial foundations.

Simply Wall St. 3 months ago

OBIO

ACIU

QSI
High Growth Tech Stocks in the United States

Over the last 7 days, the United States market has dropped 2.6%, yet it has risen by 24% over the past year, with earnings expected to grow by 15% per annum in the coming years. In this context of fluctuating performance and anticipated growth, identifying high growth tech stocks involves looking at companies with innovative technologies and strong potential for future expansion.

Simply Wall St. 3 months ago

MGTX

ACIU

CDNA
AC Immune announces interim safety, tolerability data from ABATE Phase 1b/2

AC Immune (ACIU) SA announced interim safety and tolerability data from the ABATE Phase 1b/2 trial of ACI-24.060 in individuals living with Down syndrome, DS. Targeting toxic forms of amyloid beta, ACI-24.060 is an active immunotherapy covering Abeta 1-15. The interim analysis was based on data from the first two cohorts of individuals with DS receiving low-dose and mid-dose ACI-24.060. DS subjects in the interim analysis have been treated for up to one year, with no serious adverse events relat

TipRanks 4 months ago

ACIU
AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome

AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome ACI-24.060 was generally safe and well tolerated in individuals with Down syndrome with no serious adverse events related to the study drugNo cases of amyloid-related imaging abnormalities observed in this study populationBased upon these findings, AC Immune plans to open the high-dose cohort in ABATE in individuals with Down syndrome Lausanne, Switzerland, December 10, 2024 – AC Immune SA (NASDAQ: A

GlobeNewswire 4 months ago

ACIU
AC Immune’s stock jumps after Parkinson’s therapy shows signs of benefit

AC Immune’s Phase II trial showed an increase in anti-a-syn antibodies following treatment with the Parkinson’s disease vaccine like therapy.

Pharmaceutical Technology 5 months ago

ACIU
AC Immune reports interim results from Phase 2 trial of ACI-7104.056

AC Immune (ACIU) announced positive interim safety and immunogenicity data from the Phase 2 VacSYn clinical trial evaluating ACI-7104.056, its wholly owned anti-alpha-synuclein active immunotherapy candidate, for the treatment of patients with early Parkinson’s disease. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We are encouraged by these initial Phase 2 safety and immunogenicity data on our ACI-7104.056 active immunotherapy being studied in early Parkinson’s disease. The level of immu

TipRanks 5 months ago

ACIU
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease

AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein antibody levels on average 16-fold higher than placebo after 3 immunizations100% of patients receiving ACI-7104.056 responded against the target antigenACI-7104.056 is well tolerated with no clinically relevant safety issues reported to date Lausanne, Switzerland, November 14, 2024 – AC Immune SA (NASD

GlobeNewswire 5 months ago

ACIU
AC Immune to Present at the Jefferies 2024 London Healthcare Conference

AC Immune to Present at the Jefferies 2024 London Healthcare Conference Lausanne, Switzerland, November 13, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company Management will participate in a fireside chat and one-on-one investor meetings during the Jefferies 2024 London Healthcare Conference, taking place in-person in London on November 19-21, 2024. The fireside chat will take

GlobeNewswire 5 months ago

ACIU
AC Immune SA Beat Analyst Profit Forecasts, And Analysts Have New Estimates

It's been a good week for AC Immune SA ( NASDAQ:ACIU ) shareholders, because the company has just released its latest...

Simply Wall St. 5 months ago

ACIU
AC Immune: Q3 Earnings Snapshot

LAUSANNE, Switzerland (AP) — AC Immune SA (ACIU) on Tuesday reported third-quarter net income of $6.4 million, after reporting a loss in the same period a year earlier. The Lausanne, Switzerland-based company said it had net income of 6 cents per share. The results topped Wall Street expectations.

Associated Press Finance 5 months ago

ACIU

Performance Overview

Return	IMR.SG	S&P 500 (^GSPC)
YTD	-47.44%	-8.60%
1-Year	-38.22%	+6.02%
3-Year	-60.88%	+25.85%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

AC Immune SA (IMR.SG)

AC Immune reports interim outcomes from trial of Parkinson’s therapy

AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease

AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025

ACIU Stock Crashes 18.3% in a Month: Buy, Sell or Hold?

AC Immune (NASDAQ:ACIU) investors are sitting on a loss of 52% if they invested five years ago

AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update

AC Immune (ACIU) Upgraded to Strong Buy: Here's What You Should Know

AC Immune to Participate in Upcoming Investor Conferences

Down -9.7% in 4 Weeks, Here's Why You Should You Buy the Dip in AC Immune (ACIU)

3 US Penny Stocks With Market Caps Over $100M To Consider

US Penny Stocks Spotlight: AC Immune And Two Others To Consider

High Growth Tech Stocks in the United States

AC Immune announces interim safety, tolerability data from ABATE Phase 1b/2

AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome

AC Immune’s stock jumps after Parkinson’s therapy shows signs of benefit

AC Immune reports interim results from Phase 2 trial of ACI-7104.056

AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease

AC Immune to Present at the Jefferies 2024 London Healthcare Conference

AC Immune SA Beat Analyst Profit Forecasts, And Analysts Have New Estimates

AC Immune: Q3 Earnings Snapshot

Performance Overview